Nitin Ohri, MD, MS

Albert Einstein College of Medicine

Bronx, NY

Disclosures:

Employment: none
Compensation: Regeneron: Consultant, Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: 11/10/2023 ;AstraZeneca: Consultant, Research Grants, Research Funding, Research Salary Support, Grant Research Funding, Honoraria-End Date: Present ;BeOne Medicines:Role Topic Description-End Date: To Present ;Shanghai Henlius Biotech:Role Topic Description-End Date: To Present ;Koneksa: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: T
Ownership: none
Leadership: none

Presentations

Sep 26

AstraZeneca Pharmaceuticals LP - Tumor Board: Integrating Immunotherapy With Definitive and Perioperative Radiation Strategies in Stage I-III NSCLC

Commonwealth A-B, Westin Boston Seaport District Hotel

06:30pm - 08:00pm ET

Industry Satellite Symposium

Sep 28

QP 16 - Lung Quick Pitch: Locally Advanced NSCLC

Room 107

05:00pm - 06:00pm ET

Lung Cancer/Thoracic Malignancies

Sep 28

Questions and Answers

Room 107

05:35pm - 05:55pm ET

Sep 29

275 - FLT3 Ligand (CDX-301) and Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer

Room 156

12:50pm - 01:00pm ET

Sep 29

3514 - Impact of Changes in the IASLC 9th Edition Lung Cancer Staging System in Patients Treated with Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Poster Hall - Exhibit Hall A

03:45pm - 05:00pm ET

Sep 29

Complex Reirradiation Cases

Room 156

05:32pm - 05:47pm ET